Pasithea Therapeutics Corp.

Equities

KTTA

US70261F2020

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-25 pm EDT			5-day change	1st Jan Change
7.24 ^USD	+4.17%		+1.83%	-2.16%

Apr. 24	Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers	CI
Mar. 29	Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tranche Update on Pasithea Therapeutics Corp.'s Equity Buyback Plan announced on July 20, 2023.

September 14, 2023 at 09:11 am EDT

From July 20, 2023 to September 8, 2023, the company has repurchased 5,323,451 shares, representing 21.86% for $3.73 million. With this, the company has completed the repurchase of 5,323,451 shares, representing 21.86% for $3.73 million under the buyback announced on July 20, 2023.

Latest news about Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers	Apr. 24	CI
Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004	Feb. 13	CI
Top Premarket Decliners	Jan. 12	MT
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position	Jan. 08	CI
Pasithea Therapeutics Shares Rise on FDA Clearance to Evaluate PAS-004 in Advanced Cancer Patients	Jan. 02	MT
Pasithea Therapeutics Gets FDA Acceptance for PAS-004 IND Application	Jan. 02	DJ
Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer Patients	Jan. 02	CI
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	Dec. 12	MT
Pasithea Therapeutics Gets Positive Response From FDA Meeting for Rare Cancer Treatment	Nov. 29	DJ
Pasithea Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Pasithea Therapeutics Corp. Selects PAS-003 Lead Development Candidate	Nov. 09	CI
Tranche Update on Pasithea Therapeutics Corp.'s Equity Buyback Plan announced on July 20, 2023.	23-09-14	CI
Pasithea Therapeutics Corp.'s Equity Buyback announced on July 20, 2023 has expired with 5,323,451 shares, representing 20.36% for $3.73 million.	23-09-07	CI
Pasithea Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Pasithea Therapeutics Corp. announces an Equity Buyback for 5,714,285 shares, for $4 million.	23-08-09	CI
Pasithea Therapeutics Corp. authorizes a Buyback Plan.	23-08-09	CI
Pasithea Therapeutics Corp. Publishes Study in Proceedings of the National Academy of Sciences Related to its PAS-003 Drug Discovery Program	23-08-01	CI
Pasithea Therapeutics' Board Authorizes Share Repurchase Program Through $4 Million Tender Offer; Shares Rise	23-07-20	MT
Pasithea Therapeutics Corp. announces an Equity Buyback for 5,714,285 shares, representing 21.86% for $4 million.	23-07-20	CI
Pasithea Therapeutics Corp. authorizes a Buyback Plan.	23-07-19	CI
Lucy Scientific Discovery Inc. cancelled the acquisition of Pasithea Therapeutics Corp..	23-07-19	CI
Lucy Scientific Discovery Reiterates Proposal to Acquire Pasithea Therapeutics	23-06-29	MT
Pasithea Therapeutics Confirms Unsolicited Takeover Proposal From Lucy Scientific Discovery	23-06-06	MT
Lucy Scientific Discovery Proposes to Acquire Pasithea Therapeutics	23-06-05	MT

Chart Pasithea Therapeutics Corp.

Duration

Period

More charts

Company Profile

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PASITHEA THERAPEUTICS CORP.	-2.16%	7.55M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs